Does the media favor MRNA or BBIO?

In the previous week, Moderna had 13 more articles in the media than BridgeBio Pharma. MarketBeat recorded 26 mentions for Moderna and 13 mentions for BridgeBio Pharma. Moderna's average media sentiment score of 0.55 beat BridgeBio Pharma's score of 0.36 indicating that Moderna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 9 Very Positive mention(s) 8 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive BridgeBio Pharma 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, BBIO or NTRA?

Natera has higher revenue and earnings than BridgeBio Pharma. Natera is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BridgeBio Pharma $713.07M 19.86 -$724.93M -$3.57 N/A Natera $2.31B 20.56 -$208.16M -$1.36 N/A

Does the media prefer BBIO or NTRA?

In the previous week, Natera had 6 more articles in the media than BridgeBio Pharma. MarketBeat recorded 19 mentions for Natera and 13 mentions for BridgeBio Pharma. Natera's average media sentiment score of 1.21 beat BridgeBio Pharma's score of 0.36 indicating that Natera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Natera 11 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RVMD or BBIO?

In the previous week, Revolution Medicines had 1 more articles in the media than BridgeBio Pharma. MarketBeat recorded 14 mentions for Revolution Medicines and 13 mentions for BridgeBio Pharma. Revolution Medicines' average media sentiment score of 1.20 beat BridgeBio Pharma's score of 0.36 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive BridgeBio Pharma 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, BIIB or BBIO?

Biogen has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen $9.89B 3.24 $1.29B $5.65 38.43 BridgeBio Pharma $713.07M 19.86 -$724.93M -$3.57 N/A

Does the media prefer BIIB or BBIO?

In the previous week, BridgeBio Pharma had 2 more articles in the media than Biogen. MarketBeat recorded 13 mentions for BridgeBio Pharma and 11 mentions for Biogen. Biogen's average media sentiment score of 1.10 beat BridgeBio Pharma's score of 0.36 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ALNY or BBIO?

In the previous week, Alnylam Pharmaceuticals had 1 more articles in the media than BridgeBio Pharma. MarketBeat recorded 14 mentions for Alnylam Pharmaceuticals and 13 mentions for BridgeBio Pharma. Alnylam Pharmaceuticals' average media sentiment score of 1.12 beat BridgeBio Pharma's score of 0.36 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 8 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

BridgeBio Pharma (BBIO) Competitors

$72.44 -0.06 (-0.08%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$70.25 -2.19 (-3.02%)

As of 09/11/2026 07:57 PM Eastern

Compare

BBIO vs. MRNA, NTRA, RVMD, BIIB, and ALNY

Should you buy BridgeBio Pharma stock or one of its competitors? BridgeBio Pharma's main competitors and comparable companies include Moderna (MRNA), Natera (NTRA), Revolution Medicines (RVMD), Biogen (BIIB), and Alnylam Pharmaceuticals (ALNY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BridgeBio Pharma compare to Moderna?

Moderna (NASDAQ:MRNA) and BridgeBio Pharma (NASDAQ:BBIO) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

BridgeBio Pharma has a net margin of -97.03% compared to Moderna's net margin of -141.43%. BridgeBio Pharma's return on equity of 0.00% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
BridgeBio Pharma	-97.03%	N/A	-61.19%

In the previous week, Moderna had 13 more articles in the media than BridgeBio Pharma. MarketBeat recorded 26 mentions for Moderna and 13 mentions for BridgeBio Pharma. Moderna's average media sentiment score of 0.55 beat BridgeBio Pharma's score of 0.36 indicating that Moderna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	9 Very Positive mention(s)	8 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive
BridgeBio Pharma	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

BridgeBio Pharma has lower revenue, but higher earnings than Moderna. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$2.21B	26.01	-$2.82B	-$7.99	N/A
BridgeBio Pharma	$713.07M	19.86	-$724.93M	-$3.57	N/A

Moderna currently has a consensus price target of $76.72, indicating a potential downside of 46.71%. BridgeBio Pharma has a consensus price target of $102.61, indicating a potential upside of 41.65%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts clearly believe BridgeBio Pharma is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

Moderna has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

75.3% of Moderna shares are owned by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

BridgeBio Pharma beats Moderna on 9 of the 16 factors compared between the two stocks.

How does BridgeBio Pharma compare to Natera?

BridgeBio Pharma (NASDAQ:BBIO) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

Natera has higher revenue and earnings than BridgeBio Pharma. Natera is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$713.07M	19.86	-$724.93M	-$3.57	N/A
Natera	$2.31B	20.56	-$208.16M	-$1.36	N/A

99.8% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 99.9% of Natera shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 5.1% of Natera shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Natera has a net margin of -7.11% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
Natera	-7.11%	-11.38%	-7.87%

In the previous week, Natera had 6 more articles in the media than BridgeBio Pharma. MarketBeat recorded 19 mentions for Natera and 13 mentions for BridgeBio Pharma. Natera's average media sentiment score of 1.21 beat BridgeBio Pharma's score of 0.36 indicating that Natera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Natera	11 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BridgeBio Pharma presently has a consensus price target of $102.61, indicating a potential upside of 41.65%. Natera has a consensus price target of $330.83, indicating a potential upside of 0.58%. Given BridgeBio Pharma's higher probable upside, equities analysts plainly believe BridgeBio Pharma is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Natera	1 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83

BridgeBio Pharma has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Natera has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market.

Summary

Natera beats BridgeBio Pharma on 11 of the 16 factors compared between the two stocks.

How does BridgeBio Pharma compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and BridgeBio Pharma (NASDAQ:BBIO) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

Revolution Medicines has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Revolution Medicines presently has a consensus price target of $226.17, indicating a potential upside of 10.99%. BridgeBio Pharma has a consensus price target of $102.61, indicating a potential upside of 41.65%. Given BridgeBio Pharma's higher possible upside, analysts clearly believe BridgeBio Pharma is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.95
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

Revolution Medicines has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
BridgeBio Pharma	-97.03%	N/A	-61.19%

In the previous week, Revolution Medicines had 1 more articles in the media than BridgeBio Pharma. MarketBeat recorded 14 mentions for Revolution Medicines and 13 mentions for BridgeBio Pharma. Revolution Medicines' average media sentiment score of 1.20 beat BridgeBio Pharma's score of 0.36 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
BridgeBio Pharma	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

BridgeBio Pharma has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	N/A	N/A	-$1.13B	-$8.82	N/A
BridgeBio Pharma	$713.07M	19.86	-$724.93M	-$3.57	N/A

Summary

BridgeBio Pharma beats Revolution Medicines on 9 of the 16 factors compared between the two stocks.

How does BridgeBio Pharma compare to Biogen?

Biogen (NASDAQ:BIIB) and BridgeBio Pharma (NASDAQ:BBIO) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

In the previous week, BridgeBio Pharma had 2 more articles in the media than Biogen. MarketBeat recorded 13 mentions for BridgeBio Pharma and 11 mentions for Biogen. Biogen's average media sentiment score of 1.10 beat BridgeBio Pharma's score of 0.36 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Biogen has a net margin of 8.32% compared to BridgeBio Pharma's net margin of -97.03%. Biogen's return on equity of 11.18% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
BridgeBio Pharma	-97.03%	N/A	-61.19%

Biogen presently has a consensus price target of $230.14, suggesting a potential upside of 5.98%. BridgeBio Pharma has a consensus price target of $102.61, suggesting a potential upside of 41.65%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts clearly believe BridgeBio Pharma is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

87.9% of Biogen shares are owned by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are owned by institutional investors. 0.3% of Biogen shares are owned by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Biogen has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.24	$1.29B	$5.65	38.43
BridgeBio Pharma	$713.07M	19.86	-$724.93M	-$3.57	N/A

Biogen has a beta of 0.17, suggesting that its stock price is 83% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

Summary

Biogen beats BridgeBio Pharma on 9 of the 17 factors compared between the two stocks.

How does BridgeBio Pharma compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and BridgeBio Pharma (NASDAQ:BBIO) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

Alnylam Pharmaceuticals has a net margin of 15.26% compared to BridgeBio Pharma's net margin of -97.03%. Alnylam Pharmaceuticals' return on equity of 84.93% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
BridgeBio Pharma	-97.03%	N/A	-61.19%

Alnylam Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	8.96	$313.75M	$5.38	46.22
BridgeBio Pharma	$713.07M	19.86	-$724.93M	-$3.57	N/A

Alnylam Pharmaceuticals has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Alnylam Pharmaceuticals currently has a consensus target price of $376.67, indicating a potential upside of 51.47%. BridgeBio Pharma has a consensus target price of $102.61, indicating a potential upside of 41.65%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Alnylam Pharmaceuticals is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

In the previous week, Alnylam Pharmaceuticals had 1 more articles in the media than BridgeBio Pharma. MarketBeat recorded 14 mentions for Alnylam Pharmaceuticals and 13 mentions for BridgeBio Pharma. Alnylam Pharmaceuticals' average media sentiment score of 1.12 beat BridgeBio Pharma's score of 0.36 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	8 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Alnylam Pharmaceuticals beats BridgeBio Pharma on 12 of the 17 factors compared between the two stocks.

Get BridgeBio Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BBIO vs. The Competition

Export

Metric	BridgeBio Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$14.17B	$3.86B	$7.16B	$12.73B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-20.29	14.18	274.10	25.29
Price / Sales	19.86	1,482.03	656.00	99.06
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	-6.73	15.12	10.33	6.20
Net Income	-$724.93M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-3.21%	-4.35%	-3.35%	-2.35%
1 Month Performance	-13.60%	-0.04%	-0.43%	-2.77%
1 Year Performance	41.46%	40.63%	19.21%	7.63%

BridgeBio Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BBIO BridgeBio Pharma	3.4553 of 5 stars	$72.44 -0.1%	$102.61 +41.6%	+37.7%	$14.17B	$713.07M	N/A	839	Analyst Forecast
MRNA Moderna	2.1312 of 5 stars	$140.34 +1.7%	$80.53 -42.6%	+467.0%	$55.09B	$1.94B	N/A	4,700	Trending News Analyst Forecast
NTRA Natera	2.1519 of 5 stars	$321.96 -1.3%	$319.38 -0.8%	+89.2%	$47.03B	$2.31B	N/A	6,140	Positive News Analyst Forecast
RVMD Revolution Medicines	2.9764 of 5 stars	$205.57 -1.1%	$200.74 -2.4%	+340.7%	$44.56B	$11.58M	N/A	250	Positive News Analyst Forecast Insider Trade
BIIB Biogen	3.2673 of 5 stars	$216.65 -0.8%	$227.79 +5.1%	+45.9%	$32.28B	$10.03B	38.35	7,500	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BBIO) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BridgeBio Pharma (BBIO) Competitors

BBIO vs. MRNA, NTRA, RVMD, BIIB, and ALNY

How does BridgeBio Pharma compare to Moderna?

Summary

How does BridgeBio Pharma compare to Natera?

Summary

How does BridgeBio Pharma compare to Revolution Medicines?

Summary

How does BridgeBio Pharma compare to Biogen?

Summary

How does BridgeBio Pharma compare to Alnylam Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBIO vs. The Competition

BridgeBio Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BridgeBio Pharma (BBIO) Competitors

BBIO vs. MRNA, NTRA, RVMD, BIIB, and ALNY

How does BridgeBio Pharma compare to Moderna?

Is MRNA or BBIO more profitable?

Does the media favor MRNA or BBIO?

Which has better earnings & valuation, MRNA or BBIO?

Do analysts rate MRNA or BBIO?

Which has more volatility and risk, MRNA or BBIO?

Do insiders & institutionals have more ownership in MRNA or BBIO?

Summary

How does BridgeBio Pharma compare to Natera?

Which has higher earnings and valuation, BBIO or NTRA?

Do insiders & institutionals have more ownership in BBIO or NTRA?

Is BBIO or NTRA more profitable?

Does the media prefer BBIO or NTRA?

Do analysts recommend BBIO or NTRA?

Which has more risk and volatility, BBIO or NTRA?

Summary

How does BridgeBio Pharma compare to Revolution Medicines?

Which has more risk & volatility, RVMD or BBIO?

Do analysts recommend RVMD or BBIO?

Is RVMD or BBIO more profitable?

Does the media prefer RVMD or BBIO?

Do institutionals & insiders have more ownership in RVMD or BBIO?

Which has stronger earnings & valuation, RVMD or BBIO?

Summary

How does BridgeBio Pharma compare to Biogen?

Does the media prefer BIIB or BBIO?

Is BIIB or BBIO more profitable?

Do analysts rate BIIB or BBIO?

Do institutionals and insiders hold more shares of BIIB or BBIO?

Which has better valuation & earnings, BIIB or BBIO?

Which has more volatility & risk, BIIB or BBIO?

Summary

How does BridgeBio Pharma compare to Alnylam Pharmaceuticals?

Is ALNY or BBIO more profitable?

Which has preferable valuation and earnings, ALNY or BBIO?

Which has more volatility & risk, ALNY or BBIO?

Do institutionals & insiders have more ownership in ALNY or BBIO?

Do analysts prefer ALNY or BBIO?

Does the media favor ALNY or BBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBIO vs. The Competition

BridgeBio Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools